Cited by 227SARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections StudiesViral Infections and Outbreaks Research

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

MERS-CoV Antibody Responses 1 Year after Symptom Onset, South Korea, 2015

Open access

Choe, Pyoeng Gyun, Perera, R.A.P.M., Park, Wan Beom, Song, Kyoung-Ho, Bang, Ji Hwan, Kim, Eu Suk, Kim, Hong Bin, Ko, Long Wei Ronald, Park, Sang Won, Kim, Nam-Joong, Lau, Eric H.Y., Poon, Leo L.M., Peiris, Malik, Oh, Myoung-don·2017·Emerging Infectious Diseases

DOI 10.3201/eid2307.170310PMC PMC5512479

Open this paper in CoChat — free account Open PDF

Abstract

We investigated the kinetics of the Middle East respiratory syndrome coronavirus (MERS-CoV) neutralizing and spike protein antibody titers over the course of 1 year in 11 patients who were confirmed by reverse transcription PCR to have been infected during the outbreak in South Korea in 2015. Robust antibody responses were detected in all survivors who had severe disease; responses remained detectable, albeit with some waning, for <1 year. The duration of viral RNA detection (but not viral load) in sputum significantly correlated with the antibody response magnitude. The MERS S1 ELISA antibody titers correlated well with the neutralizing antibody response. Antibody titers in 4 of 6 patients who had mild illness were undetectable even though most had evidence of pneumonia. This finding implies that MERS-CoV seroepidemiologic studies markedly underestimate the extent of mild and asymptomatic infection. Obtaining convalescent-phase plasma with high antibody titers to treat MERS will be challenging.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.3201/eid2307.170310

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Figure Middle East respiratory syndrome (MERS) coronavirus antibody titers in serially collected serum samples from 11 patients with reverse transcription PCR–confirmed symptomatic MERS, South Korea, 2015. PRNT90 titers (A) and MERS spike protein (S1) ELISA OD ratios (B) were determined at multiple time points 0 to >400 days after disease onset. The limit of detection was 10 for the PRNT, and the cutoff between negative and borderline samples for the S1 ELISA was an OD ratio of 0.8. Letters in key indicate patients; red indicates those with severe disease, and green indicates those with nonsevere disease. OD, optical density; PRNT90, >90% plaque-reduction neutralization test.CC BY · PubMed Central

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The Effectiveness of Convalescent Plasma and Hyperimmune Immunoglobulin for the Treatment of Severe Acute Respiratory Infections of Viral Etiology: A Systematic Review and Exploratory Meta-analysis
Mair-Jenkins, J., Saavedra-Campos, M., Baillie, J. K., Cleary, P. R., Khaw, F.-M., Lim, W. S., Makki, S., Rooney, K., Convalescent Plasma Study Group, Nguyen‐Van‐Tam, J. S., et al. (2014) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiu396 · Cited by 985
The time course of the immune response to experimental coronavirus infection of man
Callow, K. A., Parry, H. F., Sergeant, M., & Tyrrell, D. A. J. (1990) · Epidemiology and Infection · doi:10.1017/s0950268800048019 · Cited by 598
Viral Shedding and Antibody Response in 37 Patients With Middle East Respiratory Syndrome Coronavirus Infection
Corman, V. M., Albarrak, A. M., Omrani, A. S., Albarrak, M. M., Farah, M. E., Almasri, M. M., Muth, D., Sieberg, A., Meyer, B., Assiri, A. M., et al. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ951 · Cited by 370
Disappearance of Antibodies to SARS-Associated Coronavirus after Recovery
Cao, W.-C., Liu, W., Zhang, P.-H., Zhang, F., & Richardus, J. H. (2007) · New England Journal of Medicine · doi:10.1056/nejmc070348 · Cited by 367
Seroepidemiology for MERS coronavirus using microneutralisation and pseudoparticle virus neutralisation assays reveal a high prevalence of antibody in dromedary camels in Egypt, June 2013
Perera, R. A. P. M., Wang, P., Gomaa, M. R., El‐Shesheny, R., Kandeil, A., Bagato, O., Siu, L. Y.-L., Shehata, M., Kayed, A. E., Moatasim, Y., et al. (2013) · Eurosurveillance · doi:10.2807/1560-7917.es2013.18.36.20574 · Cited by 323
Self-citation
Middle East Respiratory Syndrome Coronavirus Outbreak in the Republic of Korea, 2015
Prevention, K. C. F. D. C. A. (2015) · Osong Public Health and Research Perspectives · doi:10.1016/j.phrp.2015.08.006 · Cited by 262
Feasibility of Using Convalescent Plasma Immunotherapy for MERS-CoV Infection, Saudi Arabia
Arabi, Y. M., Hajeer, A. H., Luke, T. C., Raviprakash, K. S., Balkhy, H. H., Johani, S. A., Al‐Dawood, A., Al-Qahtani, S. M., Al‐Omari, A., Al-Hameed, F. M., et al. (2016) · Emerging infectious diseases · doi:10.3201/eid2209.151164 · Cited by 248
Viral Load Kinetics of MERS Coronavirus Infection
Oh, M., Park, W. B., Choe, P. G., Choi, S., Kim, J., Chae, J., Park, S. S., Kim, E.-C., Oh, H. S., Kim, E. J., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmc1511695 · Cited by 224
Self-citation
Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol
Arabi, Y. M., Balkhy, H. H., Hajeer, A. H., Bouchama, A., Hayden, F. G., Al‐Omari, A., Al-Hameed, F. M., Taha, Y., Shindo, N., Whitehead, J., et al. (2015) · SpringerPlus · doi:10.1186/s40064-015-1490-9 · Cited by 202
Persistence of Antibodies against Middle East Respiratory Syndrome Coronavirus
Payne, D. C., Iblan, I., Rha, B., Alqasrawi, S., Haddadin, A., Nsour, M. A., Alsanouri, T., Ali, S. S., Harcourt, J. L., Miao, C., et al. (2016) · Emerging infectious diseases · doi:10.3201/eid2210.160706 · Cited by 201

Show all 17 references

Sorted by citations

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals
Grifoni, A., Weiskopf, D., Ramirez, S. I., Mateus, J., Dan, J. M., Moderbacher, C. R., Rawlings, S. A., Sutherland, A., Premkumar, L., Jadi, R. S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.015 · Cited by 3,595
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,237
Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections
Long, Q.-X., Tang, X.-J., Shi, Q.-L., Li, Q., Deng, H.-J., Yuan, J., Hu, J.-L., Xu, W., Zhang, Y., Lv, F.-J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0965-6 · Cited by 2,686
A serological assay to detect SARS-CoV-2 seroconversion in humans
Amanat, F., Stadlbauer, D., Strohmeier, S., Nguyen, T. H. O., Chromikova, V., McMahon, M., Jiang, K., Arunkumar, G. A., Jurczyszak, D., Polanco, J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0913-5 · Cited by 1,769
Severe Acute Respiratory Syndrome Coronavirus 2−Specific Antibody Responses in Coronavirus Disease Patients
Okba, N. M. A., Müller, M. A., Li, W., Wang, C., GeurtsvanKessel, C. H., Corman, V. M., Lamers, M. M., Sikkema, R. S., de Bruin, E., Chandler, F. D., et al. (2020) · Emerging Infectious Diseases · doi:10.3201/eid2607.200841 · Cited by 1,614
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
Zhang, Y., Zeng, G., Pan, H., Li, C., Hu, Y., Chu, K., Han, W., Chen, Z., Tang, R., Yin, W., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30843-4 · Cited by 1,504
Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans
Seow, J., Graham, C., Merrick, B., Acors, S., Pickering, S., Steel, K. J. A., Hemmings, O., O’Byrne, A., Kouphou, N., Galao, R. P., et al. (2020) · Nature Microbiology · doi:10.1038/s41564-020-00813-8 · Cited by 1,419
SARS-CoV-2 Vaccines: Status Report
Amanat, F., & Krammer, F. (2020) · Immunity · doi:10.1016/j.immuni.2020.03.007 · Cited by 1,120
The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients
Premkumar, L., Segovia-Chumbez, B., Jadi, R., Martinez, D. R., Raut, R., Markmann, A. J., Cornaby, C., Bartelt, L., Weiss, S., Park, Y., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.abc8413 · Cited by 868
Infection of dogs with SARS-CoV-2
Sit, T. H. C., Brackman, C. J., Ip, S. M., Tam, K. W. S., Law, P. Y.-T., To, E. M. W., Yu, V. Y. T., Sims, L. D., Tsang, D. N. C., Chu, D. K. W., et al. (2020) · Nature · doi:10.1038/s41586-020-2334-5 · Cited by 787
Self-citation
A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity
Huang, A. T., Garcia-Carreras, B., Hitchings, M. D. T., Yang, B., Katzelnick, L. C., Rattigan, S. M., Borgert, B. A., Moreno, C. A., Solomon, B. D., Trimmer-Smith, L., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18450-4 · Cited by 1,026
Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study
Hansen, C. H., Michlmayr, D., Gubbels, S. M., Mølbak, K., & Ethelberg, S. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00575-4 · Cited by 586
Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses
Schmidt, F., Weisblum, Y., Muecksch, F., Hoffmann, H.-H., Michailidis, E., Lorenzi, J. C. C., Mendoza, P., Rutkowska, M., Bednarski, E., Gaebler, C., et al. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20201181 · Cited by 572
Testing for SARS-CoV-2 (COVID-19): a systematic review and clinical guide to molecular and serological in-vitro diagnostic assays
Marca, A. L., Capuzzo, M., Paglia, T., Roli, L., Trenti, T., & Nelson, S. M. (2020) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2020.06.001 · Cited by 394
An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment
GeurtsvanKessel, C. H., Okba, N. M. A., Igloi, Z., Bogers, S., Embregts, C. W. E., Laksono, B. M., Leijten, L., Rokx, C., Rijnders, B., Rahamat-Langendoen, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17317-y · Cited by 361
Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison
Ainsworth, M. A., Andersson, M. I., Auckland, K., Baillie, J. K., Barnes, E. J., Beer, S., Beveridge, A., Bibi, S., Blackwell, L., Borak, M., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30634-4 · Cited by 341
Use of Convalescent Plasma Therapy in Two COVID-19 Patients with Acute Respiratory Distress Syndrome in Korea
Ahn, J. Y., Sohn, Y., Lee, S. H., Cho, Y., Hyun, J. H., Baek, Y. J., Jeong, S. J., Kim, J. H., Ku, N. S., Yeom, J., et al. (2020) · Journal of Korean Medical Science · doi:10.3346/jkms.2020.35.e149 · Cited by 352
Self-citation
The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection
Kellam, P., & Barclay, W. (2020) · Journal of General Virology · doi:10.1099/jgv.0.001439 · Cited by 353
Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival
Dispinseri, S., Secchi, M., Pirillo, M. F., Tolazzi, M., Borghi, M., Brigatti, C., Angelis, M. L. D., Baratella, M., Bazzigaluppi, E., Venturi, G., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22958-8 · Cited by 338
Neutralizing antibody titres in SARS-CoV-2 infections
Lau, E. H. Y., Tsang, O. T., Hui, D. S. C., Kwan, M. Y. W., Chan, W. H., Chiu, S. S. S., Ko, R. L., Chan, K. H., Cheng, S. M. S., Perera, R. A. P. M., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20247-4 · Cited by 331
Self-citation
Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020
Perera, R. A. P. M., Mok, C. K. P., Tsang, O. T., Lv, H., Ko, R. L., Wu, N. C., Yuan, M., Leung, W.-S., Chan, J. M., Chik, T. S., et al. (2020) · Eurosurveillance · doi:10.2807/1560-7917.es.2020.25.16.2000421 · Cited by 319
Self-citation
Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial
Modjarrad, K., Roberts, C. C., Mills, K. T., Castellano, A. R., Paolino, K. M., Muthumani, K., Reuschel, E. L., Robb, M. L., Racine, T., Oh, M., et al. (2019) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(19)30266-x · Cited by 308
Self-citation
ORF8 and ORF3b antibodies are accurate serological markers of early and late SARS-CoV-2 infection
Hachim, A., Kavian, N., Cohen, C. A., Chin, A. W. H., Chu, D. K. W., Mok, C. K. P., Tsang, O. T., Yeung, Y. C., Perera, R. A. P. M., Poon, L. L. M., et al. (2020) · Nature Immunology · doi:10.1038/s41590-020-0773-7 · Cited by 270
Self-citation
Dynamics of Neutralizing Antibody Titers in the Months After Severe Acute Respiratory Syndrome Coronavirus 2 Infection
Crawford, K. H. D., Dingens, A. S., Eguia, R., Wolf, C. R., Wilcox, N., Logue, J. K., Shuey, K., Casto, A. M., Fiala, B., Wrenn, S., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa618 · Cited by 265
Prospects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Serological Approaches for COVID-19: Epidemiologic Perspective on Surveillance and Control
Lee, C. Y., Lin, R. T. P., Rénia, L., & Ng, L. F. P. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00879 · Cited by 262
Changes in SARS-CoV-2 Spike versus Nucleoprotein Antibody Responses Impact the Estimates of Infections in Population-Based Seroprevalence Studies
Fenwick, C. W., Croxatto, A., Coste, A. T., Pojer, F., André, C., Pellaton, C., Farina, A., Campos, J., Hacker, D. L., Lau, K., et al. (2020) · Journal of Virology · doi:10.1128/jvi.01828-20 · Cited by 226
What policy makers need to know about COVID-19 protective immunity
Altmann, D. M., Douek, D. C., & Boyton, R. J. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30985-5 · Cited by 223
Middle East respiratory syndrome: what we learned from the 2015 outbreak in the Republic of Korea
Oh, M., Park, W. B., Park, S., Choe, P. G., Bang, J. H., Song, K., Kim, E. S., Kim, H. B., & Kim, N. J. (2018) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2018.031 · Cited by 215
Self-citation
Three-Month Follow-Up Study of Survivors of Coronavirus Disease 2019 after Discharge
Liang, L., Yang, B., Jiang, N., Fu, W., He, X., Zhou, Y., Ma, W., & Wang, X. (2020) · Journal of Korean Medical Science · doi:10.3346/jkms.2020.35.e418 · Cited by 216
Magnitude and Kinetics of Anti–Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Responses and Their Relationship to Disease Severity
Lynch, K. L., Whitman, J. D., Lacanienta, N. P., Beckerdite, E. W., Kastner, S. A., Shy, B. R., Goldgof, G. M., Levine, A. G., Bapat, S. P., Stramer, S. L., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa979 · Cited by 207
The durability of immunity against reinfection by SARS-CoV-2: a comparative evolutionary study
Townsend, J. P., Hassler, H. B., Wang, Z., Miura, S., Singh, J., Kumar, S., Ruddle, N. H., Galvani, A. P., & Dornburg, A. (2021) · The Lancet Microbe · doi:10.1016/s2666-5247(21)00219-6 · Cited by 186
Quality of life reported by survivors after hospitalization for Middle East respiratory syndrome (MERS)
Batawi, S., Tarazan, N., Al-Raddadi, R. M., Qasim, E. A., Sindi, A., Johni, S. A., Al-Hameed, F. M., Arabi, Y. M., Uyeki, T. M., & Alraddadi, B. M. (2019) · Health and Quality of Life Outcomes · doi:10.1186/s12955-019-1165-2 · Cited by 162
Emergence of a novel human coronavirus threatening human health
Poon, L. L. M., & Peiris, M. J. S. (2020) · Nature Medicine · doi:10.1038/s41591-020-0796-5 · Cited by 158
Self-citation
Epidemiological research priorities for public health control of the ongoing global novel coronavirus (2019-nCoV) outbreak
Cowling, B. J., & Leung, G. M. (2020) · Eurosurveillance · doi:10.2807/1560-7917.es.2020.25.6.2000110 · Cited by 156
Sustained cellular immune dysregulation in individuals recovering from SARS-CoV-2 infection
Files, J. K., Boppana, S., Perez, M. D., Sarkar, S., Lowman, K. E., Qin, K., Sterrett, S., Carlin, E., Bansal, A., Sabbaj, S., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci140491 · Cited by 158
Mutations in the Spike Protein of Middle East Respiratory Syndrome Coronavirus Transmitted in Korea Increase Resistance to Antibody-Mediated Neutralization
Kleine‐Weber, H., Elzayat, M. T., Wang, L., Graham, B. S., Müller, M. A., Drosten, C., Pöhlmann, S., & Hoffmann, M. (2018) · Journal of Virology · doi:10.1128/jvi.01381-18 · Cited by 143
Exposure to SARS-CoV-2 generates T-cell memory in the absence of a detectable viral infection
Wang, Z., Yang, X., Zhong, J., Zhou, Y., Tang, Z., Zhou, H., He, J., Mei, X., Tang, Y., Lin, B., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22036-z · Cited by 131
Immunoglobulins in the treatment of COVID-19 infection: Proceed with caution!
Nguyen, A. A., Habiballah, S. B., Platt, C. D., Geha, R. S., Chou, J. S., & McDonald, D. R. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108459 · Cited by 130
Emerging respiratory infections: The infectious disease pathology of SARS, MERS, pandemic influenza, and Legionella
Bradley, B. T., & Bryan, A. B. (2019) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2019.04.006 · Cited by 124
Convalescent Plasma Therapy for COVID-19: State of the Art
Focosi, D., Anderson, A. O., Tang, J. W.-T., & Tuccori, M. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00072-20 · Cited by 125
Multiplex assays for the identification of serological signatures of SARS-CoV-2 infection: an antibody-based diagnostic and machine learning study
Rosado, J., Pelleau, S., Cockram, C. A., Merkling, S. H., Nekkab, N., Demeret, C., Meola, A., Kernéis, S., Terrier, B., Fafi‐Kremer, S., et al. (2020) · The Lancet Microbe · doi:10.1016/s2666-5247(20)30197-x · Cited by 128
Reinfection With SARS-CoV-2: Implications for Vaccines
Cohen, J. I., & Burbelo, P. D. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1866 · Cited by 111
Longitudinal analysis of antibody dynamics in COVID-19 convalescents reveals neutralizing responses up to 16 months after infection
Yang, Y., Yang, M., Peng, Y., Liang, Y., Wei, J., Xing, L., Guo, L., Li, X., Li, J., Wang, J., et al. (2022) · Nature Microbiology · doi:10.1038/s41564-021-01051-2 · Cited by 111
Serologic responses to SARS-CoV-2 infection among hospital staff with mild disease in eastern France
Fafi-Kremer, S., Bruel, T., Madec, Y., Grant, R., Tondeur, L., Grzelak, L., Staropoli, I., Anna, F., Souque, P., Fernandes-Pellerin, S., et al. (2020) · eBioMedicine · doi:10.1016/j.ebiom.2020.102915 · Cited by 108
Rational Vaccine Design in the Time of COVID-19
Burton, D., & Walker, L. (2020) · Cell Host and Microbe · doi:10.1016/j.chom.2020.04.022 · Cited by 112
Asymptomatic Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection: Extent and implications for infection control: A systematic review
Al‐Tawfiq, J. A., & Gautret, P. (2018) · Travel Medicine and Infectious Disease · doi:10.1016/j.tmaid.2018.12.003 · Cited by 99
MERS-CoV as an emerging respiratory illness: A review of prevention methods
Baharoon, S. A., & Memish, Z. A. (2019) · Travel Medicine and Infectious Disease · doi:10.1016/j.tmaid.2019.101520 · Cited by 99
Age-related susceptibility to coronavirus infections: role of impaired and dysregulated host immunity
Channappanavar, R., & Perlman, S. M. (2020) · Journal of Clinical Investigation · doi:10.1172/jci144115 · Cited by 94
The 2020 race towards SARS-CoV-2 specific vaccines
Karpiński, T. M. M., Ożarowski, M., Seremak‐Mrozikiewicz, A., Wolski, H., & Włodkowic, D. (2020) · Theranostics · doi:10.7150/thno.53691 · Cited by 95
Performance of nucleocapsid and spike-based SARS-CoV-2 serologic assays
Tehrani, Z. R., Saadat, S., Saleh, E., Ouyang, X., Constantine, N. T., DeVico, A. L., Harris, A. D., Lewis, G. K., Kottilil, S., & Sajadi, M. M. (2020) · PLoS ONE · doi:10.1371/journal.pone.0237828 · Cited by 90
Follow-up study on COVID-19 survivors one year after discharge from hospital
Zhao, Y., Yang, C., An, X., Xiong, Y., Shang, Y., He, J., Qiu, Y., Zhang, N., Huang, L., Jia, J., et al. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.09.017 · Cited by 93
Enhanced inflammation in New Zealand white rabbits when MERS-CoV reinfection occurs in the absence of neutralizing antibody
Houser, K. V., Broadbent, A., Gretebeck, L., Vogel, L., Lamirande, E. W., Sutton, T. C., Bock, K. W., Minai, M., Orandle, M. S., Moore, I. N., et al. (2017) · PLoS Pathogens · doi:10.1371/journal.ppat.1006565 · Cited by 88
Immune response following infection with SARS‐CoV ‐2 and other coronaviruses: A rapid review
Murchú, É. Ó., Byrne, P., Walsh, K. A., Carty, P. G., Connolly, M. A., Gascun, C. F. D., Jordan, K., Keoghan, M., O’Brien, K. K., O’Neill, M., et al. (2020) · Reviews in Medical Virology · doi:10.1002/rmv.2162 · Cited by 85
The durability of natural infection and vaccine-induced immunity against future infection by SARS-CoV-2
Townsend, J. P., Hassler, H. B., Sah, P., Galvani, A. P., & Dornburg, A. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2204336119 · Cited by 85
T-cell responses to MERS coronavirus infection in people with occupational exposure to dromedary camels in Nigeria: an observational cohort study
Mok, C. K. P., Zhu, A., Zhao, J., Lau, E. H. Y., Wang, J., Chen, Z., Zhuang, Z., Wang, Y., Alshukairi, A. N., Baharoon, S. A., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30599-5 · Cited by 83
Self-citation
Immunomodulatory Effects of Azithromycin Revisited: Potential Applications to COVID-19
Venditto, V. J., Haydar, D., Abdel‐Latif, A., Gensel, J. C., Anstead, M., Pitts, M. G., Creameans, J. W., Kopper, T. J., Peng, C., & Feola, D. J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.574425 · Cited by 90
Stereotypic neutralizing V H antibodies against SARS-CoV-2 spike protein receptor binding domain in patients with COVID-19 and healthy individuals
Kim, S. I., Noh, J., Kim, S., Choi, Y. G., Yoo, D. K., Lee, Y., Lee, H., Jung, J., Kang, C. K., Song, K., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abd6990 · Cited by 82
Self-citation
Lasting antibody and T cell responses to SARS-CoV-2 in COVID-19 patients three months after infection
Jiang, X.-L., Wang, G.-L., Zhao, X.-N., Yan, F.-H., Lin, Y., Kou, Z.-Q., Ji, S.-X., Zhang, X.-L., Li, C.-B., Duan, L., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21155-x · Cited by 77
Middle East Respiratory Syndrome Coronavirus Infection Dynamics and Antibody Responses among Clinically Diverse Patients, Saudi Arabia
Al-Abdely, H. M., Midgley, C. M., Alkhamis, A. M., Abedi, G. R., Lu, X., Binder, A. M., Alanazi, K. H., Tamin, A., Banjar, W. M., Lester, S. N., et al. (2019) · Emerging infectious diseases · doi:10.3201/eid2504.181595 · Cited by 81
Systemic Corticosteroid Therapy May Delay Viral Clearance in Patients with Middle East Respiratory Syndrome Coronavirus Infection
Hui, D. S. C. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201712-2371ed · Cited by 81
Serologic responses of 42 MERS-coronavirus-infected patients according to the disease severity
Ko, J., Müller, M. A., Seok, H., Park, G. E., Lee, J. Y., Cho, S. Y., Ha, Y. E., Baek, J. Y., Ys, K., Kang, J., et al. (2017) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2017.07.006 · Cited by 77
Sensitive and Specific Detection of Low-Level Antibody Responses in Mild Middle East Respiratory Syndrome Coronavirus Infections
Okba, N. M. A., Raj, V. S., Widjaja, I., GeurtsvanKessel, C. H., de Bruin, E., Chandler, F. D., Park, W. B., Kim, N. J., Farag, E., Al-Hajri, M., et al. (2019) · Emerging infectious diseases · doi:10.3201/eid2510.190051 · Cited by 79
Self-citation
Development of a SARS-CoV-2 Total Antibody Assay and the Dynamics of Antibody Response over Time in Hospitalized and Nonhospitalized Patients with COVID-19
Vogelzang, E. H., Loeff, F. C., Derksen, N. I. L., Kruithof, S., Heer, P. O., van Mierlo, G. J., Linty, F., Mok, J. Y., van Esch, W. J. E., de Bruin, S., et al. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.2000767 · Cited by 78
Ethical Implementation of Immunity Passports During the COVID-19 Pandemic
Voo, T. C., Clapham, H., & Tam, C. C. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa352 · Cited by 78
Treatment of COVID-19 with convalescent plasma: lessons from past coronavirus outbreaks
Wooding, D. J., & Bach, H. (2020) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2020.08.005 · Cited by 78
Prevention and treatment of respiratory viral infections: Presentations on antivirals, traditional therapies and host-directed interventions at the 5th ISIRV Antiviral Group conference
McKimm‐Breschkin, J. L., Jiang, S., Hui, D. S. C., Beigel, J. H., Govorkova, E. A., & Lee, N. L. S. (2017) · Antiviral Research · doi:10.1016/j.antiviral.2017.11.013 · Cited by 79
A single-dose mRNA vaccine provides a long-term protection for hACE2 transgenic mice from SARS-CoV-2
Huang, Q., Ji, K., Tian, S., Wang, F., Huang, B., Tong, Z., Tan, S., Hao, J., Wang, Q., Tan, W., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21037-2 · Cited by 79
Immuno-informatics design of a multimeric epitope peptide based vaccine targeting SARS-CoV-2 spike glycoprotein
Chukwudozie, O. S., Gray, C. M., Fagbayi, T., Chukwuanukwu, R. C., Oyebanji, V. O., Bankole, T., Adewole, A. R., & Daniel, E. M. (2021) · PLoS ONE · doi:10.1371/journal.pone.0248061 · Cited by 74
COVID-19 pandemic control: balancing detection policy and lockdown intervention under ICU sustainability
Arthur Charpentier, A., Élie, R., Laurière, M., & Tran, V. C. (2020) · Mathematical Modelling of Natural Phenomena · doi:10.1051/mmnp/2020045 · Cited by 947
Waning antibody responses in COVID-19: what can we learn from the analysis of other coronaviruses?
Hamady, A., Lee, J., & Loboda, Z. (2021) · Infection · doi:10.1007/s15010-021-01664-z · Cited by 66
Rapid decline of neutralizing antibodies is associated with decay of IgM in adults recovered from mild COVID-19
Harrington, W. E., Trakhimets, O., Andrade, D. V., Dambrauskas, N., Raappana, A., Jiang, Y., Houck, J., Selman, W., Yang, A., Vigdorovich, V. I., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100253 · Cited by 65
SARS-CoV-2 (COVID-19) serology: implications for clinical practice, laboratory medicine and public health
Caeseele, P. G. V., Bailey, D., Forgie, S. E. D., Dingle, T. C., Krajden, M., & for the COVID-19 Immunity Task Force (2020) · Canadian Medical Association Journal · doi:10.1503/cmaj.201588 · Cited by 65
Seroprevalence of SARS-CoV-2 significantly varies with age: Preliminary results from a mass population screening
Pagani, G., Conti, F., Giacomelli, A., Bernacchia, D., Rondanin, R., Prina, A., Scolari, V. F., Gandolfi, C. E., Castaldi, S., Marano, G., et al. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.09.021 · Cited by 64
What Have We Learned About Middle East Respiratory Syndrome Coronavirus Emergence in Humans? A Systematic Literature Review
Dawson, P., Malik, M. R., Parvez, F., & Morse, S. S. (2019) · Vector-Borne and Zoonotic Diseases · doi:10.1089/vbz.2017.2191 · Cited by 59
Kinetics of the Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Response and Serological Estimation of Time Since Infection
Pelleau, S., Woudenberg, T., Rosado, J., Donnadieu, F., García, L., Obadia, T., Gardais, S., Elgharbawy, Y., Velay, A., Gonzalez, M., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab375 · Cited by 64
Critical role of neutralizing antibody for SARS-CoV-2 reinfection and transmission
Kim, Y., Kim, S., Park, S., Kim, E.-H., Yu, K.-M., Chang, J.-H., Kim, E. J., Casel, M. A. B., Rollon, R., Jang, S., et al. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.1872352 · Cited by 62
Self-citation
Disappearance of antibodies to SARS-CoV-2 in a -COVID-19 patient after recovery
Liu, A., Wang, W., Zhao, X., Zhou, X., Yang, D., Lu, M., & Lv, Y. (2020) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2020.07.009 · Cited by 59
Cellular and Humoral Immune Responses in Covid-19 and Immunotherapeutic Approaches
Hasan, A., Al‐Ozairi, E., Albaqsumi, Z., Ahmad, R., & Al‐Mulla, F. (2021) · ImmunoTargets and Therapy · doi:10.2147/itt.s280706 · Cited by 56
SARS-CoV-2 neutralizing antibodies in patients with varying severity of acute COVID-19 illness
Jeewandara, C., Jayathilaka, D., Gomes, L., Wijewickrama, A., Narangoda, E., Idampitiya, D., Guruge, D., Wijayamuni, R., Manilgama, S. R., Ogg, G. S., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-81629-2 · Cited by 51
The Rise of SARS-CoV-2 Variants and the Role of Convalescent Plasma Therapy for Management of Infections
Moubarak, M., Kasozi, K. I., Hetta, ‏. F., Shaheen, H. M., Rauf, A., Al-Kuraishy, H. M., Qusti, S. Y., Alshammari, E. M., Ayikobua, E. T., Ssempijja, F., et al. (2021) · Life · doi:10.3390/life11080734 · Cited by 57
Negative Clinical Evolution in COVID-19 Patients Is Frequently Accompanied With an Increased Proportion of Undifferentiated Th Cells and a Strong Underrepresentation of the Th1 Subset
Gutiérrez‐Bautista, J. F., Rodríguez-Nicolás, A., Rosales‐Castillo, A., Jiménez, P., Garrido, F., Anderson, P. O., Ruiz‐Cabello, F., & López‐Ruz, M. Á. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.596553 · Cited by 56
The Antibody Response to SARS-CoV-2 Infection
Hueston, L., Kok, J., Guibone, A., McDonald, D., Hone, G., Goodwin, J., Carter, I. W. J., Basile, K., Sandaradura, I., Maddocks, S., et al. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa387 · Cited by 50
Experimental re-infected cats do not transmit SARS-CoV-2
Gaudreault, N. N., Carossino, M., Morozov, I., Trujillo, J. D., Meekins, D. A., Madden, D. W., Cool, K. R., Artiaga, B. L., McDowell, C. D., Bold, D., et al. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.1902753 · Cited by 56
Immunity certification for COVID-19: ethical considerations
Voo, T. C., Reis, A. A., Thome, B. D. C., Ho, C. W.-L., Tam, C. C., Cirino, C. K., Emanuel, E., Beca, J. P., Littler, K., Smith, M. J., et al. (2020) · Bulletin of the World Health Organization · doi:10.2471/blt.20.280701 · Cited by 50
Phenotypic and genetic characterization of MERS coronaviruses from Africa to understand their zoonotic potential
Zhou, Z., Hui, K. P. Y., So, R. T. Y., Lv, H., Perera, R. A. P. M., Chu, D. K. W., Gelaye, E., Oyas, H., Njagi, O. N., Abayneh, T., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2103984118 · Cited by 48
Self-citation
Implications of COVID‐19 for an ageing population
Holt, N. R., Neumann, F., McNeil, J. J., & Cheng, A. C. (2020) · The Medical Journal of Australia · doi:10.5694/mja2.50785 · Cited by 46
Humoral Response Dynamics Following Infection with SARS-CoV-2Preprint
Grandjean, L., Saso, A., Ortiz, A. T., Lam, T., Hatcher, J., Thistlethwayte, R., Harris, M., Best, T., Johnson, M., Wagstaffe, H. R., et al. (2020) · medRxiv · doi:10.1101/2020.07.16.20155663 · Cited by 44
Interim Guidelines on Antiviral Therapy for COVID-19
Kim, S. B., Huh, K., Heo, J. Y., Joo, E., Kim, Y. J., Choi, W. S., Kim, Y., Seo, Y. B., Yoon, Y. K., Ku, N. S., et al. (2020) · Infection and Chemotherapy · doi:10.3947/ic.2020.52.2.281 · Cited by 41
A Cross-Sectional Study Examining the Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies in a University Student Population
Tilley, K. B., Ayvazyan, V., Martinez, L. C., Nanda, N., Kawaguchi, E. S., O’Gorman, M. R. G., Conti, D. V., Gauderman, W. J., & Orman, S. V. (2020) · Journal of Adolescent Health · doi:10.1016/j.jadohealth.2020.09.001 · Cited by 42
SARS-CoV-2 Vaccine Development: An Overview and Perspectives
Liu, Y., Wang, K., Massoud, T. F., & Paulmurugan, R. (2020) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00109 · Cited by 40
Diagnostic Efficiency of Three Fully Automated Serology Assays and Their Correlation with a Novel Surrogate Virus Neutralization Test in Symptomatic and Asymptomatic SARS-COV-2 Individuals
Younes, S. N., Al-Jighefee, H. T., Shurrab, F. M., Al‐Sadeq, D. W., Younes, N., Dargham, S. R., Al-Dewik, N. I. E., Qotba, H. A., Syed, M. A., Alnuaimi, A. S., et al. (2021) · Microorganisms · doi:10.3390/microorganisms9020245 · Cited by 41
Comparative Serological Study for the Prevalence of Anti-MERS Coronavirus Antibodies in High- and Low-Risk Groups in Qatar
Kahlout, R. A. A., Nasrallah, G. K., Farag, E., Wang, L., Lattwein, E., Müller, M. A., Zowalaty, M. E. E., Al‐Romaihi, H. E., Graham, B. S., Thani, A. A. A., et al. (2019) · Journal of Immunology Research · doi:10.1155/2019/1386740 · Cited by 38
Exploring the therapeutic potential of forkhead box O for outfoxing COVID-19
Cheema, P. S., Nandi, D., & Nag, A. (2021) · Open Biology · doi:10.1098/rsob.210069 · Cited by 37
SARS-CoV-2: Pathogenesis, and Advancements in Diagnostics and Treatment
Khalaf, K., Papp, N., Chou, J. T.-T., Hana, D., Mackiewicz, A. A., & Kaczmarek, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.570927 · Cited by 39
Transmissibility of MERS-CoV Infection in Closed Setting, Riyadh, Saudi Arabia, 2015
Kerkhove, M. D. V., Alaswad, S., Assiri, A. M., Perera, R. A. P. M., Peiris, M. J. S., Bushra, H. E. E., & BinSaeed, A. A. (2019) · Emerging infectious diseases · doi:10.3201/eid2510.190130 · Cited by 34
Self-citation
Differential Antibody Response to Inactivated COVID-19 Vaccines in Healthy Subjects
Zhang, J., Xing, S., Liang, D., Hu, W. G., Ke, C., He, J., Yuan, R., Huang, Y., Li, Y., Liu, D., et al. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.791660 · Cited by 34
COVID-19: imbalanced cell-mediated immune response drives to immunopathology
Wang, J., Li, Q., Qiu, Y., & Lu, H. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2122579 · Cited by 36
Development and validation of different indirect ELISAs for MERS-CoV serological testing
Hashem, A. M., Alamri, S. S., Alsubhi, T. L., Siddiq, L. A., Hassan, A. M., Alawi, M., Alhabbab, R. Y., Hindawi, S., Mohammed, O. B., Amor, N. M. S., et al. (2019) · Journal of Immunological Methods · doi:10.1016/j.jim.2019.01.005 · Cited by 32
Unresolved questions in the zoonotic transmission of MERS
Peiris, M. J. S., & Perlman, S. M. (2022) · Current Opinion in Virology · doi:10.1016/j.coviro.2021.12.013 · Cited by 33
Self-citation

Authors: Choe, P. G., Perera, R. A. P. M., Park, W. B., Song, K.-H., Bang, J. H., Kim, E. S., Kim, H. B., Ko, L. W. R., Park, S. W., Kim, N.-J., Lau, E. H. Y., Poon, L. L. M., Peiris, M., & Oh, M.-D.
Affiliations: Seoul National University (KR)
Corresponding author: Oh, Myoung-don
ORCID: Choe, Pyoeng Gyun
Perera, R.A.P.M.
Park, Wan Beom
Song, Kyoung-Ho
Bang, Ji Hwan
Kim, Eu Suk
Kim, Hong Bin
Park, Sang Won
Kim, Nam-Joong
Lau, Eric H.Y.
Poon, Leo L.M.
Peiris, Malik
Oh, Myoung-don
Venue: Emerging Infectious Diseases
Publisher: Centers for Disease Control and Prevention (CDC)
Published: 2017-07
Volume: 23
Issue: 7
Pages: 1079-1084
ISSN: 1080-6040 (ISSN-L)
1080-6059
DOI: 10.3201/eid2307.170310
PMC: PMC5512479
OpenAlex: W2612594162
Cited by: 227
References: 17
Citations by year: 2026: 7 · 2025: 3 · 2024: 8 · 2023: 12 · 2022: 21 · 2021: 60 · 2020: 91 · 2019: 13 · 2018: 7 · 2017: 5
FWCI: 24.63
Type: journal article
Language: en
Open access: diamond
doi.org
Licence: cc-by
Locations: Emerging infectious diseases (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
The HKU Scholars Hub (University of Hong Kong) (submittedVersion)
Funders: Seoul National University
Korea Health Industry Development Institute (HI15C3227)
Seoul National University Hospital
Hong Kong Government
National Institutes of Health
Health and Medical Research Fund
National Institute of Allergy and Infectious Diseases (HHSN272201400003C)
Topics: Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
Health Sciences › Medicine › Infectious Diseases › Viral Infections and Outbreaks Research
Keywords: MERS-CoV, neutralizing antibodies, spike protein antibodies, antibody kinetics, antibody waning, seroconversion, convalescent plasma
MeSH terms: Antibodies, Viral, Disease Outbreaks, Enzyme-Linked Immunosorbent Assay, Follow-Up Studies, Humans, Neutralization Tests, Seroepidemiologic Studies, Coronavirus Infections, History, 21st Century, Republic of Korea, Antibodies, Neutralizing, Spike Glycoprotein, Coronavirus, Middle East Respiratory Syndrome Coronavirus

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

MERS-CoV Antibody Responses 1 Year after Symptom Onset, South Korea, 2015

Abstract

Overview

Integrity signals

Figures

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks